Many drugs in development aim to delay, slow or reverse symptoms of Alzheimer’s, but which are causing the biggest stir?

This week England’s health spending watchdog rejected a new Alzheimer’s drug – the second such drug it has turned down this year.

Both donanemab and lecanemab were approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), yet the National Institute for Health and Care Excellence (Nice) said their benefits were too small to justify their costs, while there have also been concerns over potential side effects – such as brain swelling and bleeding.